Filing Flows › Health Care › Castle Biosciences (CSTL)
Castle Biosciences (CSTL) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Castle Biosciences (CSTL) Q3 2026 earnings results →
Q3 2026 Revenue up 24% year over year to $103M · 4¢ of every $1 of revenue lost · operating margin -2.7%
Castle Biosciences made $103M in Q3 2026 (+24% Y/Y): Non-Dermatologic $55.0M, Dermatologic $47.9M. Operating margin -2.7%, net loss $4.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $102.9M in Q3 2026, up 24% year over year and down 1% from the previous quarter. Non-Dermatologic was the largest line at 53% of revenue. Non-Dermatologic added $20.5M year over year (up 59%), 103% of the total change. Dermatologic declined 1%.
Operating costs exceeded revenue by $2.7M, an operating margin of -2.7%. Total costs grew 18% against revenue growth of 24%. The fastest-growing cost line was Cost of revenue (+28%). The quarter ended with a net loss of $4.1M, wider than the previous quarter's $2.1M loss.
Operating cash flow was $19.7M (down 13% year over year). Non-cash charges added back $4.2M of depreciation and amortization and $11.2M of share-based compensation. Working capital and other items added $8.4M. Capital expenditures of $7.5M left free cash flow of $12.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $103M | +24% | -2.7% | −$4.1M | $19.7M |
| Q2 2026 | 10-Q | Jul 30, 2026 | $104M | +20% | -3.0% | −$2.1M | $15.2M |
| Q1 2026 | 10-Q | May 6, 2026 | $83.7M | -5% | -22.0% | −$14.5M | −$22.1M |
| Q4 2025 | 10-K | Feb 26, 2026 | $87.0M | +0.8% | -4.4% | −$2.3M | $26.9M |
| Q3 2025 | 10-Q | Nov 3, 2025 | $83.0M | -3% | -8.2% | −$501K | $22.6M |
| Q2 2025 | 10-Q | Aug 4, 2025 | $86.2M | -0.9% | -4.9% | $4.5M | $20.8M |
| Q1 2025 | 10-Q | May 5, 2025 | $88.0M | +21% | -31.7% | −$25.8M | −$6.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Castle Biosciences
As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, “Castle Biosciences,” the “Company,” “we,” “us” and “our” refer to Castle Biosciences, Inc., a Delaware Corporation. Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (“BE”), atopic dermatitis (“AD”), uveal melanoma (“UM”).
In its own words, from its 10-K, filed Feb 26, 2026.
Castle Biosciences against its Services-Medical Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +24% against the peers' median +24%. Operating margin: -2.7% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CSTL Castle Biosciences | Q3 2026 | $103M | +24% | -2.7% |
| LH Labcorp Holdings | Q3 2026 | $3.8B | +7% | 10.6% |
| DGX Quest Diagnostics | Q3 2026 | $3.1B | +10% | 15.5% |
| NTRA Natera | Q3 2026 | $794M | +34% | -8.6% |
| FTRE Fortrea Holdings | Q3 2026 | $692M | -1% | 2.2% |
| RDNT RadNet | Q2 2026 | $623M | +25% | 6.3% |
| GH Guardant Health | Q3 2026 | $361M | +36% | -36.8% |
| CAI Caris Life Sciences | Q3 2026 | $275M | +27% | 7.0% |
| LMRI Lumexa Imaging Holdings | Q2 2026 | $264M | +5% | 8.7% |
Source: Castle Biosciences 10-Q on SEC EDGAR · CIK 1447362 · Services-Medical Laboratories
Guidance and outlook
13F: who owns CSTL and who is buying
More on CSTL
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results